Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

100 trials found

Recruiting 999,999 target

Molecular Genetics Studies of Cancer Patients and Their Relatives

City of Hope Medical Center

NCT04185935

Recruiting Phase 3 11,000 target

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Boehringer Ingelheim

NCT06531824

Recruiting Phase 3 6,000 target

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

Pfizer

NCT07160244

Recruiting Phase 3 5,200 target

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Colorado Prevention Center

NCT06008197

Recruiting 5,000 target

Deep Brain Stimulation (DBS) Retrospective Outcomes Study

Boston Scientific Corporation

NCT03664609

Recruiting 5,000 target

The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry

Yale University

NCT06030063

Recruiting NA 4,000 target

The Fourth Left Atrial Appendage Occlusion Study

Hamilton Health Sciences Corporation

NCT05963698

Recruiting NA 4,000 target

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

University of British Columbia

NCT04634240

Recruiting 3,000 target

Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay

Sequenom

NCT02586389

Recruiting NA 2,250 target

PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

Edwards Lifesciences

NCT04889872

Recruiting 2,000 target

ASSESS ALL ALS Study

St. Joseph's Hospital and Medical Center, Phoenix

NCT06578195

Recruiting Phase 3 1,900 target

REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool

Senseye

NCT07280065

Recruiting Phase 4 1,710 target

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Insud Pharma

NCT05303636

Recruiting 1,500 target

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

Boston Scientific Corporation

NCT06827262

Recruiting 1,500 target

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Boston Scientific Corporation

NCT02071134

Recruiting Phase 1 1,405 target

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

ModernaTX

NCT05992935

Recruiting Phase 2 1,217 target

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Eli Lilly and Company

NCT06143956

Recruiting Phase 3 1,200 target

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Eli Lilly and Company

NCT06993792

Recruiting Phase 3 1,095 target

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Genmab

NCT06191744

Recruiting 1,000 target

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

M.D. Anderson Cancer Center

NCT04739072

Recruiting NA 1,000 target

First Face Training Evaluation in Tribal Communities

Cambridge Health Alliance

NCT05998005

Recruiting Phase 3 1,000 target

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Merck Sharp & Dohme

NCT06841354

Recruiting Phase 3 970 target

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Direct Biologics

NCT05354141

Recruiting Phase 2 920 target

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

NCT04589845

Recruiting 900 target

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

Ascendis Pharma Endocrinology Division A/S

NCT05820672

Recruiting Phase 2 900 target

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

SWOG Cancer Research Network

NCT06769126

Recruiting Phase 3 900 target

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

GlaxoSmithKline

NCT06855160

Recruiting Phase 3 880 target

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

AstraZeneca

NCT06692738

Recruiting Phase 3 868 target

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Merck Sharp & Dohme

NCT06077760

Recruiting Phase 3 795 target

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Janssen Research & Development

NCT06208150

Recruiting Phase 3 750 target

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

Hoffmann-La Roche

NCT06094010

Recruiting Phase 4 730 target

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

Chris Goss

NCT05548283

Recruiting Phase 3 723 target

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

Sanofi

NCT07088068

Recruiting Phase 3 723 target

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Pfizer

NCT06641466

Recruiting NA 699 target

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

Boston Scientific Corporation

NCT07187115

Recruiting Phase 3 680 target

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Merck Sharp & Dohme

NCT06623422

Recruiting Phase 3 675 target

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

AbbVie

NCT06461897

Recruiting Phase 3 640 target

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Pfizer

NCT05156398

Recruiting Phase 3 620 target

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

AstraZeneca

NCT06467357

Recruiting Phase 2 600 target

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

PPD Development

NCT06703073

Recruiting Phase 3 600 target

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Hoffmann-La Roche

NCT06793215

Recruiting 600 target

PREVENT ALL ALS Study

St. Joseph's Hospital and Medical Center, Phoenix

NCT06581861

Recruiting Phase 3 600 target

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Eli Lilly and Company

NCT06972459

Recruiting 600 target

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

GT Medical Technologies

NCT04427384

Recruiting Phase 3 600 target

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

Alliance for Clinical Trials in Oncology

NCT05008848

Recruiting Phase 3 600 target

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Eli Lilly and Company

NCT06972472

Recruiting Phase 2 594 target

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Merck Sharp & Dohme

NCT06890884

Recruiting Phase 2 590 target

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Bristol-Myers Squibb

NCT07063745

Recruiting Phase 3 580 target

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

argenx

NCT06684847

Recruiting NA 573 target

Prospective Multi-Center Trial for FemBloc Permanent Birth Control

Femasys

NCT05977751

Recruiting Phase 3 572 target

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

AstraZeneca

NCT06346392

Recruiting Phase 2 550 target

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

Synairgen Research

NCT06999603

Recruiting Phase 3 544 target

A Randomized Trial to Evaluate Sequential vs Simultaneous Patching

Jaeb Center for Health Research

NCT04378790

Recruiting Phase 3 540 target

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Novartis Pharmaceuticals

NCT04557462

Recruiting Phase 2 540 target

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

AstraZeneca

NCT06932263

Recruiting Phase 3 528 target

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

SWOG Cancer Research Network

NCT06470243

Recruiting Phase 3 510 target

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Eli Lilly and Company

NCT06338995

Recruiting NA 500 target

Stress Management for College Students

Boise State University

NCT06888141

Recruiting Phase 2 500 target

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Giselle Sholler

NCT02559778

Recruiting NA 500 target

Maternal Stress on Human Milk and Infant Outcomes

University of Idaho

NCT04821544

Recruiting 500 target

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

Ascendis Pharma Endocrinology Division A/S

NCT05775523

Recruiting Phase 2 470 target

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Bristol-Myers Squibb

NCT07076121

Recruiting Phase 3 460 target

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Novo Nordisk A/S

NCT07253285

Recruiting Phase 3 460 target

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

AbbVie

NCT06614192

Recruiting Phase 2 456 target

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Sirtsei Pharmaceuticals

NCT06254612

Recruiting Phase 3 450 target

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Eli Lilly and Company

NCT07218380

Recruiting Phase 3 450 target

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Kite, A Gilead Company

NCT06413498

Recruiting Phase 2 441 target

Neuroblastoma Maintenance Therapy Trial

Giselle Sholler

NCT02679144

Recruiting Phase 2 436 target

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

Upstream Bio

NCT06966479

Recruiting NA 432 target

Pain Management Teams Using Whole Health to Optimize Function and Safety in Veterans: The TEAMWORK Trial

VA Office of Research and Development

NCT07149870

Recruiting Phase 3 428 target

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Hoffmann-La Roche

NCT05797610

Recruiting Phase 2 416 target

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

Boehringer Ingelheim

NCT06926660

Recruiting NA 407 target

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

Boston Scientific Corporation

NCT06735534

Recruiting Phase 3 400 target

Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

Baxis Pharmaceuticals

NCT06911424

Recruiting 400 target

A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

Nicole Hamblett

NCT06504589

Recruiting NA 400 target

Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention

Seattle Institute for Biomedical and Clinical Research

NCT06390345

Recruiting Phase 3 400 target

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Boehringer Ingelheim

NCT07195695

Recruiting NA 400 target

GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

Medtronic Diabetes

NCT07228117

Recruiting Phase 3 400 target

Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis

pH-D Feminine Health

NCT07109869

Recruiting Phase 2 396 target

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

SWOG Cancer Research Network

NCT05633615

Recruiting Phase 2 375 target

LMN-201 for Prevention of C. Difficile Infection Recurrence

Lumen Bioscience

NCT05330182

Recruiting Phase 3 360 target

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Xenon Pharmaceuticals

NCT05716100

Recruiting Phase 3 350 target

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Eli Lilly and Company

NCT06937086

Recruiting Phase 3 347 target

A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition

Takeda

NCT06963827

Recruiting Phase 3 330 target

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Alliance for Clinical Trials in Oncology

NCT07000084

Recruiting Phase 3 320 target

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Canadian Cancer Trials Group

NCT06686771

Recruiting Phase 3 320 target

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

Longboard Pharmaceuticals

NCT06719141

Recruiting Phase 2 320 target

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Janssen Research & Development

NCT05963074

Recruiting Phase 3 320 target

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

National Cancer Institute (NCI)

NCT06524544

Recruiting Phase 3 308 target

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

Dr. Falk Pharma

NCT06596252

Recruiting 300 target

A Study to Assess Growth in Children With Idiopathic Short Stature

BioMarin Pharmaceutical

NCT06309979

Recruiting Phase 2 300 target

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

Vertex Pharmaceuticals Incorporated

NCT06619860

Recruiting Phase 3 300 target

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

Pfizer

NCT07013474

Recruiting NA 300 target

Desara ® One Single Incision Sling 522 Study

Caldera Medical

NCT04772131

Recruiting Phase 3 300 target

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Eli Lilly and Company

NCT06439277

Recruiting Phase 3 290 target

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Eli Lilly and Company

NCT06937099

Recruiting Phase 3 286 target

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

Dimerix Bioscience Pty

NCT05183646

Recruiting Phase 2 282 target

Study of JK07 in Patients With Chronic Heart Failure

Salubris Biotherapeutics

NCT06369298

Recruiting NA 280 target

WATER IV Prostate Cancer

PROCEPT BioRobotics

NCT06651632

Recruiting Phase 3 274 target

The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

Duchesnay

NCT05289557

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →